EPIRUS Biopharmaceuticals, Inc. (OTCMKTS:EPRSQ) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapies and vaccine candidates for the treatment of substance-use disorders and autoimmune conditions. The company’s proprietary platform leverages conjugate vaccine technology to elicit targeted immune responses against small-molecule drugs, with the goal of reducing drug distribution to the brain and minimizing abuse potential. EPIRUS’s pipeline includes lead vaccine candidates aimed at heroin, fentanyl, methamphetamine and nicotine addiction, as well as antibody-based therapies designed to neutralize toxic metabolites associated with these substances.
In addition to its addiction vaccine programs, EPIRUS has pursued research collaborations to explore immunomodulatory approaches for chronic inflammatory and autoimmune diseases. By harnessing specific carrier proteins and adjuvant combinations, the company aims to induce sustained antibody titers that can mitigate aberrant immune activity without the need for daily immunosuppressive drugs. Preclinical models have demonstrated proof-of-concept for several indications, and EPIRUS continues to evaluate safety and immunogenicity in early-stage clinical trials.
Founded in 2008 and headquartered in Frederick, Maryland, EPIRUS deploys a virtual R&D model that integrates in-house scientific expertise with external contract research organizations and academic partners. This hybrid organizational structure allows the company to maintain lean operating expenses while advancing multiple candidates through preclinical and clinical development. EPIRUS holds strategic partnerships in North America and Europe, where it collaborates on manufacturing scale-up, toxicology studies and potential regulatory filings.
Leadership at EPIRUS includes Chief Executive Officer Dr. Robin Caldwell, who brings more than 25 years of experience in biopharmaceutical development and regulatory affairs, and Chief Scientific Officer Dr. Marcus Liang, a veteran immunologist with a track record of advancing conjugate vaccines to clinic. Supported by a seasoned board of directors and advisors drawn from both large-cap pharmaceutical companies and specialized biotech firms, EPIRUS aims to address critical unmet needs in addiction medicine and beyond.
AI Generated. May Contain Errors.
